Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to com...
Search
Search covers the most recently published. For the full archive, browsethe topics.
1 result for"Roivant"